Massmutual Trust Co. FSB ADV Has $414,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Massmutual Trust Co. FSB ADV boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,937 shares of the biopharmaceutical company’s stock after buying an additional 450 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Gilead Sciences were worth $414,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. J. W. Coons Advisors LLC increased its holdings in shares of Gilead Sciences by 2.8% in the 4th quarter. J. W. Coons Advisors LLC now owns 11,130 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 300 shares during the period. Campbell & CO Investment Adviser LLC increased its holdings in shares of Gilead Sciences by 19.1% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 7,436 shares of the biopharmaceutical company’s stock valued at $602,000 after purchasing an additional 1,195 shares during the period. 1832 Asset Management L.P. increased its holdings in shares of Gilead Sciences by 31.2% in the 4th quarter. 1832 Asset Management L.P. now owns 31,171 shares of the biopharmaceutical company’s stock valued at $2,525,000 after purchasing an additional 7,411 shares during the period. Exencial Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 86.1% in the 4th quarter. Exencial Wealth Advisors LLC now owns 5,288 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 2,446 shares during the period. Finally, Morningstar Investment Services LLC increased its holdings in shares of Gilead Sciences by 124.9% in the 4th quarter. Morningstar Investment Services LLC now owns 15,191 shares of the biopharmaceutical company’s stock valued at $1,233,000 after purchasing an additional 8,437 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GILD shares. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler restated an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a report on Wednesday, September 11th. Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. BMO Capital Markets increased their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Royal Bank of Canada increased their price objective on Gilead Sciences from $74.00 to $75.00 and gave the stock a “sector perform” rating in a report on Friday. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $82.12.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock worth $3,033,340 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.5 %

GILD opened at $84.59 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $105.39 billion, a price-to-earnings ratio of 234.97, a P/E/G ratio of 2.91 and a beta of 0.18. The business has a 50 day moving average of $79.06 and a 200-day moving average of $71.93.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.64%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.